A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.


Updates from The Motley Fool

Latest updates on MannKind from Fool.com.  The Fool has written over 400 articles on MannKind.
4 Stocks I'd Avoid at All Costs

Whether you're interested in these biotech stocks or not, there are some important lessons to be ...

3 Stocks to Avoid in Biotech

Buying biotech stocks has always been a risky business, but these three are best left on the shelf.



Stock Performance

View Interactive MNKD Charts
Sponsored by

Key Data Points

Primary metrics and data points about MannKind.
Current Price: $0.52
Prev Close: $0.51
Open: $0.52
Bid: $0.51
Ask: $0.52
Day's Range: $0.51 - $0.54
52wk Range: $0.41 - $2.24
Volume: 1,886,223
Avg Vol 4,148,850
Market Cap: $250M
P/E (ttm): -0.99
EPS (ttm): ($0.52)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about MannKind.
CAPS Rating 2 out of 5
 
694 Outperform
133 Underperform
CAPS All Stars
 
75 Outperform
35 Underperform

How do you think MannKind will perform against the market?



You pick for MannKind is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Matthew J. Pfeffer, CEO

0% Approve

Based on 1 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for MannKind.

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers